After much review and public controversy, the FDA met this week and determined that flibanserin, a new medication that was hoped to be an effective treatment for female sexual arousal disorder, did not significantly improve symptoms of the disorder, and ruled against approving the medication.
Female sexual arousal disorder, also known as hypoactive sexual desire disorder, (HSDD) is a relatively new diagnosis. It was historically known as frigidity, and more attention was given to the concept of the lack of sexual desire or arousal as a biological disorder potentially treatable with pharmaceuticals. When Sildenifil (Viagra) appeared on the market with enormous publicity and profit for the pharmaceutical industry, a lack of desire in women came under consideration as a potentially treatable disease. Read more